As part of its mission to save lives and protect people’s health by increasing equitable and sustainable use of vaccines, Gavi has helped vaccinate more than 1.1 billion children in 78 lower-income countries, preventing more than 18.8 million future deaths.

See progress report       See facts and figures

Gavi’s impact

• More children survive. The increase in immunisation has helped halve childhood mortality by averting more than 18.8 million future deaths and dramatically driven down the incidence of deadly and debilitating infectious diseases.
• Nation building thrives. As children become healthier, they, their families, communities and countries are more able to be economically prosperous and socially stable. For every US$ 1 spent on immunisation in Gavi-supported countries in the 2021–2030 period, US$ 21 are saved in health care costs, lost wages and lost productivity due to illness and death. When considering the value people place on lives saved by vaccines – which is likely to include the value of costs averted plus the broader societal value of lives saved and people living longer and healthier lives – the return on investment is estimated to be US$ 54 per US$ 1 spent. In Gavi’s first 24 years, our work helped generate more than US$ 250 billion in economic benefits in the countries we support.
• And global health security improves. In the face of global challenges, such as climate change, population growth, urbanisation, human migration, fragility and conflict, Gavi has helped countries broaden vaccine coverage and improve their health systems. This makes them less susceptible and better able to prevent disease outbreaks that pose a threat to people in these countries, protecting millions of others around the world.

A Proven Model

Gavi now vaccinates more than half of the world’s children, giving it tremendous power to negotiate vaccines at prices that are affordable for the poorest countries and to remove the commercial risks that previously kept manufacturers from serving them. The number of manufacturers supplying prequalified Gavi-supported vaccines has grown, from 5 in 2001 to 19 in 2022 (with more than half based in low- and middle-income countries).

Gavi shares the cost that implementing countries pay for vaccines, which has resulted in more than 637 vaccine introductions and preventive vaccination campaigns, dramatically boosting immunisation against virulent diseases. For example, in 2000, 3% of low-income countries had introduced nationally Haemophilus influenzae type b (Hib) vaccine that protects against diseases like pneumonia and meningitis. Gavi has enabled all low-income countries to introduce this vaccine in their national programmes. Today, Gavi-supported countries continue to have higher coverage of vaccines against Hib, pneumococcus and rotavirus than the rest of the world. As of 2022, 19 countries had transitioned out of Gavi support and are fully self-financing vaccine programmes introduced with Gavi support.

Learn about our ISO certification for effective information security management.